CV Sciences (CVSI) Non-Current Debt (2013 - 2025)

CV Sciences (CVSI) posted Non-Current Debt of $387000.0 for Q4 2025, down 23.21% sequentially from $504000.0 in Q3 2025.

CV Sciences (CVSI) Non-Current Debt (2013 - 2025) Analysis & Trends

CV Sciences has reported Non-Current Debt for 8 years, with the latest figure at $387000.0 in Q4 2025.

Quarterly Non-Current Debt changed N/A year-over-year to $387000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $387000.0 (changed N/A YoY) and the FY2025 annual result came in at $387000.0, changed N/A from the prior year.
Non-Current Debt fell to $387000.0 in Q4 2025 per CVSI's latest filing, from $504000.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $1.7 million in Q1 2022 and troughed at $208000.0 in Q2 2025.
A 3-year average of $878444.4 and a median of $504000.0 in 2025 frame the typical range for Non-Current Debt.
The widest YoY moves for Non-Current Debt: up 375.21% in 2022, down 123.74% in 2022.
Over 3 years, Non-Current Debt stood at $771000.0 in 2021, then soared by 123.74% to $1.7 million in 2022, then slumped by 77.57% to $387000.0 in 2025.
According to Business Quant data, Non-Current Debt over the past three periods registered $387000.0, $504000.0, and $208000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-8.44 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	12.09 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	27.73 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	11.61 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.85 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	130.00 Mn
10	CV Sciences	4.10 Mn	3.84 Mn	1.45 Mn	-

Download Data